Welch Group LLC lessened its holdings in Bristol-Myers Squibb Company (NYSE:BMY) by 3.4% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,245 shares of the biopharmaceutical company’s stock after selling 330 shares during the quarter. Welch Group LLC’s holdings in Bristol-Myers Squibb were worth $515,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in BMY. Blue Chip Partners Inc. increased its holdings in Bristol-Myers Squibb by 0.8% during the first quarter. Blue Chip Partners Inc. now owns 2,141 shares of the biopharmaceutical company’s stock worth $116,000 after buying an additional 17 shares during the last quarter. Keel Point LLC increased its holdings in shares of Bristol-Myers Squibb by 0.3% in the first quarter. Keel Point LLC now owns 6,286 shares of the biopharmaceutical company’s stock valued at $342,000 after purchasing an additional 18 shares during the last quarter. Staley Capital Advisers Inc. increased its holdings in shares of Bristol-Myers Squibb by 0.3% in the first quarter. Staley Capital Advisers Inc. now owns 6,962 shares of the biopharmaceutical company’s stock valued at $379,000 after purchasing an additional 24 shares during the last quarter. Shayne & CO. LLC increased its holdings in shares of Bristol-Myers Squibb by 0.6% in the second quarter. Shayne & CO. LLC now owns 4,041 shares of the biopharmaceutical company’s stock valued at $225,000 after purchasing an additional 24 shares during the last quarter. Finally, Greenleaf Trust increased its holdings in shares of Bristol-Myers Squibb by 0.4% in the second quarter. Greenleaf Trust now owns 9,608 shares of the biopharmaceutical company’s stock valued at $535,000 after purchasing an additional 39 shares during the last quarter. 69.14% of the stock is currently owned by institutional investors and hedge funds.

In related news, SVP Joseph C. Caldarella sold 9,340 shares of the stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $60.00, for a total value of $560,400.00. Following the transaction, the senior vice president now directly owns 46,297 shares in the company, valued at approximately $2,777,820. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 0.23% of the stock is owned by company insiders.

Shares of Bristol-Myers Squibb Company (NYSE:BMY) opened at $62.22 on Monday. The company has a market cap of $101,835.48, a P/E ratio of 21.02, a PEG ratio of 2.45 and a beta of 1.18. Bristol-Myers Squibb Company has a 52-week low of $46.01 and a 52-week high of $66.10. The company has a current ratio of 1.59, a quick ratio of 1.46 and a debt-to-equity ratio of 0.47.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $0.75 EPS for the quarter, missing the consensus estimate of $0.77 by ($0.02). The company had revenue of $5.25 billion for the quarter, compared to analyst estimates of $5.20 billion. Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. The business’s quarterly revenue was up 6.7% compared to the same quarter last year. During the same period last year, the business earned $0.77 EPS. research analysts expect that Bristol-Myers Squibb Company will post 2.99 earnings per share for the current year.

The company also recently announced a quarterly dividend, which was paid on Wednesday, November 1st. Investors of record on Friday, October 6th were issued a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a dividend yield of 2.51%. The ex-dividend date was Thursday, October 5th. Bristol-Myers Squibb’s dividend payout ratio is currently 61.42%.

Several equities analysts have commented on BMY shares. Goldman Sachs Group, Inc. (The) reiterated a “buy” rating and issued a $63.00 price objective on shares of Bristol-Myers Squibb in a report on Wednesday, August 9th. Vetr downgraded shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating and set a $63.81 price objective on the stock. in a report on Wednesday, August 9th. Jefferies Group LLC restated a “buy” rating and issued a $63.00 price target on shares of Bristol-Myers Squibb in a research note on Wednesday, July 12th. Finally, UBS AG restated a “buy” rating and issued a $72.00 price target (up from $62.00) on shares of Bristol-Myers Squibb in a research note on Friday, October 6th. One investment analyst has rated the stock with a sell rating, ten have given a hold rating and eleven have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $64.93.

ILLEGAL ACTIVITY NOTICE: “Welch Group LLC Cuts Stake in Bristol-Myers Squibb Company (BMY)” was published by Watch List News and is owned by of Watch List News. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.watchlistnews.com/welch-group-llc-cuts-stake-in-bristol-myers-squibb-company-bmy/1681926.html.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with Analyst Ratings Network's FREE daily email newsletter.